JP2017530142A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530142A5
JP2017530142A5 JP2017517228A JP2017517228A JP2017530142A5 JP 2017530142 A5 JP2017530142 A5 JP 2017530142A5 JP 2017517228 A JP2017517228 A JP 2017517228A JP 2017517228 A JP2017517228 A JP 2017517228A JP 2017530142 A5 JP2017530142 A5 JP 2017530142A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
quizartinib
administered
volasertib
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017517228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530142A (ja
JP6708634B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/072386 external-priority patent/WO2016050749A1/en
Publication of JP2017530142A publication Critical patent/JP2017530142A/ja
Publication of JP2017530142A5 publication Critical patent/JP2017530142A5/ja
Application granted granted Critical
Publication of JP6708634B2 publication Critical patent/JP6708634B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017517228A 2014-10-01 2015-09-29 急性骨髄性白血病及び骨髄異形成症候群の併用療法iii Active JP6708634B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14187331.5 2014-10-01
EP14187331 2014-10-01
PCT/EP2015/072386 WO2016050749A1 (en) 2014-10-01 2015-09-29 Combination treatment of acute myeloid leukemia and myelodysplastic syndrome iii

Publications (3)

Publication Number Publication Date
JP2017530142A JP2017530142A (ja) 2017-10-12
JP2017530142A5 true JP2017530142A5 (cg-RX-API-DMAC7.html) 2018-11-08
JP6708634B2 JP6708634B2 (ja) 2020-06-10

Family

ID=51730328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017517228A Active JP6708634B2 (ja) 2014-10-01 2015-09-29 急性骨髄性白血病及び骨髄異形成症候群の併用療法iii

Country Status (4)

Country Link
US (1) US9867831B2 (cg-RX-API-DMAC7.html)
EP (1) EP3200879B1 (cg-RX-API-DMAC7.html)
JP (1) JP6708634B2 (cg-RX-API-DMAC7.html)
WO (1) WO2016050749A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016525532A (ja) 2013-07-26 2016-08-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 骨髄異形成症候群の処置
EP3469001A4 (en) * 2016-06-09 2020-05-06 Seattle Genetics, Inc. COMBINATIONS OF PBD-BASED ANTIBODY CONJUGATES WITH FLT3 INHIBITORS

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8303657A (nl) 1983-10-24 1985-05-17 Pharmachemie Bv Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan.
DE3537761A1 (de) 1985-10-24 1987-04-30 Bayer Ag Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure
JPH0276860A (ja) 1987-10-05 1990-03-16 Toyo Jozo Co Ltd 6−置換アルコキシ−2−オキソ−1,2−ジヒドロキノキサリン誘導体
ES2058527T3 (es) 1988-06-16 1994-11-01 Smith Kline French Lab Derivados de pirimidina condensados procedimiento y compuestos intermedios para su preparacion y composiciones farmaceuticas que los contienen.
FR2645152B1 (fr) 1989-03-30 1991-05-31 Lipha 3h-pteridinones-4, procedes de preparation et medicaments les contenant
US5043270A (en) 1989-03-31 1991-08-27 The Board Of Trustees Of The Leland Stanford Junior University Intronic overexpression vectors
CA2029651C (en) 1989-11-17 2000-06-06 David D. Davey Tricyclic pteridinones and a process for their preparation
US5198547A (en) 1992-03-16 1993-03-30 South Alabama Medical Science Foundation, Usa Process for N5-formylating tetrahydropteridines
TW274550B (cg-RX-API-DMAC7.html) 1992-09-26 1996-04-21 Hoechst Ag
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
GB9418499D0 (en) 1994-09-14 1994-11-02 Ciba Geigy Ag Process for producing n-methylated organic pigments
CO4410191A1 (es) 1994-09-19 1997-01-09 Lilly Co Eli SINTESIS DE 3-[4-(2-AMINOETOXI)BENZOIL]-2-ARIL-6- HIDROXIBENZO [b] TIOFENOS
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
AU5814596A (en) 1995-05-19 1996-11-29 Novartis Ag Process for the catalytic hydrogenation of aromatic nitro compounds
US5698556A (en) 1995-06-07 1997-12-16 Chan; Carcy L. Methotrexate analogs and methods of using same
PL194074B1 (pl) 1996-09-23 2007-04-30 Lilly Co Eli Polimorf Dihydrat D olanzapiny i preparat farmaceutyczny zawierający Dihydrat D olanzapiny
IL140868A0 (en) 1998-08-11 2002-02-10 Pfizer Prod Inc Substituted 1,8-naphthyridin-4(1h)-ones as phosphodiesterase 4 inhibitors
EE200200140A (et) 1999-09-15 2003-04-15 Warner-Lambert Company Pteridinoonid kui kinaasi inhibiitorid
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
JP2003528101A (ja) 2000-03-06 2003-09-24 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 5−アルキルピリド[2,3−d]ピリミジンチロシンキナーゼ阻害剤
DE10018783A1 (de) 2000-04-15 2001-10-25 Fresenius Kabi De Gmbh Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
US20020183292A1 (en) 2000-10-31 2002-12-05 Michel Pairet Pharmaceutical compositions based on anticholinergics and corticosteroids
DE10058119A1 (de) 2000-11-22 2002-05-23 Bayer Ag Pepinotan-Kit
US6756374B2 (en) 2001-01-22 2004-06-29 Hoffmann-La Roche Inc. Diaminothiazoles having antiproliferative activity
US6960589B2 (en) 2001-03-09 2005-11-01 Abbott Laboratories Benzimidazoles that are useful in treating sexual dysfunction
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030055026A1 (en) 2001-04-17 2003-03-20 Dey L.P. Formoterol/steroid bronchodilating compositions and methods of use thereof
WO2003020722A1 (de) 2001-09-04 2003-03-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
US6806272B2 (en) 2001-09-04 2004-10-19 Boehringer Ingelheim Pharma Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
KR20040075004A (ko) 2001-12-14 2004-08-26 어플라이드 리서치 시스템스 에이알에스 홀딩 엔.브이. 비폴리펩티드 고리에이엠피 레벨 모듈레이터를 이용한배란 유도 방법
PL372890A1 (en) 2002-05-03 2005-08-08 Schering Aktiengesellschaft Thiazolidinones and the use thereof as polo-like kinase inhibitors
FR2843114B1 (fr) 2002-08-01 2004-09-10 Poudres & Explosifs Ste Nale Procede de monomethylation d'heterocycles azotes
AU2003265348B2 (en) 2002-08-08 2007-08-16 Smithkline Beecham Corporation Thiophene compounds
US20040127504A1 (en) 2002-09-06 2004-07-01 Cowart Marlon D. Benzimidazoles that are useful in treating sexual dysfunction
ES2331119T3 (es) 2002-09-16 2009-12-22 Glaxo Group Limited Compuestos de pirazolo(3,4-b)piridina, y su uso como inhibidores de fosfodiesterasa.
SI1578446T1 (sl) * 2002-11-07 2015-07-31 Immunogen, Inc. Protitelesa proti-cd33 in metoda za zdravljenje akutne mieloidne levkemije z uporabo istega
GB2398565A (en) 2003-02-18 2004-08-25 Cipla Ltd Imatinib preparation and salts
US6861422B2 (en) 2003-02-26 2005-03-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
RS52386B (sr) 2003-02-26 2013-02-28 Boehringer Ingelheim Pharma Gmbh & Co.Kg. Dihidropteridinoni, postupak za njihovo pripremanje i njihova primena kao leka
MXPA05008526A (es) 2003-03-26 2005-10-20 Wyeth Corp Metodos y composicion inmunogenica.
CA2522158C (en) 2003-04-14 2018-03-20 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
DE102004002557A1 (de) 2004-01-17 2005-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von substituierten Pyrimido(5,4-d)pyrimidinen zur Behandlung von Atemwegserkrankungen
WO2005067935A1 (de) 2004-01-17 2005-07-28 Boehringer Ingelheim International Gmbh Verwendung von substituierten pteridinen zur behandlung von atemwegserkrankungen
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) 2004-07-09 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
DE102004034623A1 (de) 2004-07-16 2006-02-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7759485B2 (en) 2004-08-14 2010-07-20 Boehringer Ingelheim International Gmbh Process for the manufacture of dihydropteridinones
US20060074088A1 (en) 2004-08-14 2006-04-06 Boehringer Ingelheim International Gmbh Dihydropteridinones for the treatment of cancer diseases
US7728134B2 (en) 2004-08-14 2010-06-01 Boehringer Ingelheim International Gmbh Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) 2004-08-14 2006-02-16 Boehringer Ingelheim International Gmbh Storage stable perfusion solution for dihydropteridinones
US20060058311A1 (en) 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
EP1630163A1 (de) 2004-08-25 2006-03-01 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1632493A1 (de) 2004-08-25 2006-03-08 Boehringer Ingelheim Pharma GmbH & Co.KG Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
CA2575804A1 (en) 2004-08-26 2006-03-02 Boehringer Ingelheim International Gmbh Pteridinones used as plk (polo like kinase) inhibitors
JP2008510771A (ja) 2004-08-27 2008-04-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ジヒドロプテリジノン、その製造方法および医薬薬剤としてのその使用
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
DE102004058337A1 (de) 2004-12-02 2006-06-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
JP2009503014A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系疾患の治療におけるジヒドロプテリジノン
US20070117776A1 (en) 2005-11-04 2007-05-24 John Lyons Low Dose Therapy Of DNA Methylation Inhibitors
PL1948180T3 (pl) 2005-11-11 2013-09-30 Boehringer Ingelheim Int Terapia skojarzona raka polegająca na podawaniu inhibitorów EGFR/HER2
US7439358B2 (en) 2006-02-08 2008-10-21 Boehringer Ingelheim International Gmbh Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
EP1994002A1 (en) 2006-03-07 2008-11-26 AstraZeneca AB Piperidine derivatives, their process for preparation, their use as therapeutic agents and pharmaceutical compositions containing them
JP5323684B2 (ja) 2006-05-04 2013-10-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 多形体
CA2695406A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Crystalline form of a dihydropteridione derivative
JP4642085B2 (ja) 2008-01-17 2011-03-02 日本下水道事業団 予測健全度を利用した施設管理および更新計画システム
EP2100894A1 (en) 2008-03-12 2009-09-16 4Sc Ag Pyridopyrimidines used as Plk1 (polo-like kinase) inhibitors
WO2010078369A2 (en) 2008-12-30 2010-07-08 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
RU2543348C2 (ru) * 2009-03-23 2015-02-27 Эмбит Байосайенсиз Корпорейшн Способ лечения путем применения комбинированной терапии
WO2011022692A2 (en) 2009-08-20 2011-02-24 University Of Tennessee Research Foundation, The Furanopyridine cannabinoid compounds and related methods of use
EP2509592A1 (en) 2009-12-07 2012-10-17 Boehringer Ingelheim International GmbH Bibw 2992 for use in the treatment of triple negative breast cancer
WO2011101369A1 (en) 2010-02-17 2011-08-25 Boehringer Ingelheim International Gmbh Dihydropteridinones, method for production and use thereof
US8546566B2 (en) 2010-10-12 2013-10-01 Boehringer Ingelheim International Gmbh Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en) 2010-11-29 2016-06-07 Boehringer Ingelheim International Gmbh Method for treating acute myeloid leukemia
CA2820709C (en) * 2011-02-28 2016-02-16 Sunshine Lake Pharma Co., Ltd. Substituted quinoline compounds and methods of use
US20130131069A1 (en) 2011-05-13 2013-05-23 Boehringer Ingelheim International Gmbh Method for treatment of solid malignancies including advanced or metastatic solid malignancies
US9370535B2 (en) 2011-05-17 2016-06-21 Boehringer Ingelheim International Gmbh Method for treatment of advanced solid tumors
US20140154304A1 (en) * 2012-11-30 2014-06-05 Boehringer Ingelheim International Gmbh Combination therapy with volasertib

Similar Documents

Publication Publication Date Title
JP2012193216A5 (cg-RX-API-DMAC7.html)
JP2015038135A5 (cg-RX-API-DMAC7.html)
JP2015187157A5 (cg-RX-API-DMAC7.html)
JP2015523407A5 (cg-RX-API-DMAC7.html)
JP2006504795A5 (cg-RX-API-DMAC7.html)
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
JP2013121983A5 (cg-RX-API-DMAC7.html)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2013231087A5 (cg-RX-API-DMAC7.html)
JP2014526503A5 (cg-RX-API-DMAC7.html)
JP2016147915A5 (cg-RX-API-DMAC7.html)
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
JP2013516493A5 (cg-RX-API-DMAC7.html)
JP2017512194A5 (cg-RX-API-DMAC7.html)
JP2018521007A5 (cg-RX-API-DMAC7.html)
FI2683245T4 (fi) Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä
EP4410295A3 (en) Use of vibegron to treat overactive bladder
JP2016505050A5 (cg-RX-API-DMAC7.html)
JP2018039810A5 (cg-RX-API-DMAC7.html)
JP2014520874A5 (cg-RX-API-DMAC7.html)
JP2019507786A5 (cg-RX-API-DMAC7.html)
JP2019529569A5 (cg-RX-API-DMAC7.html)
JP2017530142A5 (cg-RX-API-DMAC7.html)
JP2015512948A5 (cg-RX-API-DMAC7.html)
JP2012041314A5 (cg-RX-API-DMAC7.html)